Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „tofacitinib“
Suchtreffer
Begriffe & Kennungen
Xeljanz · 4.5 · Note: Reference group is administration of tofacitinib alone. a Tofacitinib dose should be reduced to 5 mg twi
Eintrag öffnenXeljanz · 4.5 · Potential for other medicinal products to influence the pharmacokinetics (PK) of tofacitinib
Eintrag öffnenXeljanz · 4.5 · Potential for other medicinal products to influence the pharmacokinetics (PK) of tofacitinib
Eintrag öffnenXeljanz · 4.5 · Potential for other medicinal products to influence the pharmacokinetics (PK) of tofacitinib
Eintrag öffnenXeljanz · 4.5 · Potential for tofacitinib to influence the PK of other medicinal products
Eintrag öffnenXeljanz · 4.5 · Potential for tofacitinib to influence the PK of other medicinal products
Eintrag öffnenXeljanz · 4.5 · Potential for tofacitinib to influence the PK of other medicinal products
Eintrag öffnenXeljanz · 4.5 · Since tofacitinib is metabolised by CYP3A4, interaction with medicinal products that inhibit or induce CYP3A4
Eintrag öffnenXeljanz · 4.5 · Since tofacitinib is metabolised by CYP3A4, interaction with medicinal products that inhibit or induce CYP3A4
Eintrag öffnenXeljanz · 4.5 · Since tofacitinib is metabolised by CYP3A4, interaction with medicinal products that inhibit or induce CYP3A4
Eintrag öffnenXeljanz · 4.5 · Tacrolimus AUC Combined use of tofacitinib with Cmax tacrolimus should be avoided
Eintrag öffnenXeljanz · 4.5 · Tacrolimus AUC Combined use of tofacitinib with Cmax tacrolimus should be avoided
Eintrag öffnenXeljanz · 4.5 · Tacrolimus AUC Combined use of tofacitinib with Cmax tacrolimus should be avoided
Eintrag öffnenXeljanz · 4.5 · Tofacitinib exposure is decreased when coadministered with potent CYP inducers (e.g., rifampicin). Inhibitors
Eintrag öffnenXeljanz · 4.5 · Tofacitinib exposure is decreased when coadministered with potent CYP inducers (e.g., rifampicin). Inhibitors
Eintrag öffnenXeljanz · 4.5 · Tofacitinib exposure is decreased when coadministered with potent CYP inducers (e.g., rifampicin). Inhibitors
Eintrag öffnenXeljanz · 4.8 · 15 Overall, the safety profile observed in patients with UC treated with tofacitinib was consistent with the s
Eintrag öffnenXeljanz · 4.8 · 20 interruption of tofacitinib, or reduction in tofacitinib dose, resulted in decrease or normalisation of liv
Eintrag öffnenXeljanz · 4.8 · 21 Upon withdrawal of tofacitinib treatment, lipid levels returned to baseline.
Eintrag öffnenXeljanz · 4.8 · 65 The overall incidence rate of infections with tofacitinib in the long-term safety all exposure population (
Eintrag öffnen